09.04.2016 – Halle
20.04.2016 – Dortmund
01.06.2016 – Erfurt
09.07.2016 – Berlin
05.10.2016 – Düsseldorf
22.10.2016 – Dresden
02.11.2016 – Saarbrücken
Symposium der AkdÄ
im Rahmen des 122. Kongresses der DGIM
11.04.2016 - Mannheim
Symposium der AkdÄ
im Rahmen der 82. Jahrestagung des DGPT
03.03.2016 - Berlin
The Drug Commission of the German Medical Association (DCGMA) is the scientific expert committee for drug-related matters of the German Medical Association. It consists of 40 full members and approximately 135 associate members from all areas of medicine and pharmacy. The DCGMA is financed by the German Medical Association (BÄK) and the National Association of Statutory Health Insurance Physicians (KBV). All members work voluntarily for the DCGMA.
Five members and each one representative of the German Medical Association and the National Association of Statutory Health Insurance Physicians form the board of directors which determines the general directions for the work of the commission. A central office led by an executive secretary carries out the decisions and instructions of the board of directors.
In contrast to some new established institutions in the German health care system, e.g. the Institute for Quality and Efficiency in Health Care (IQWiG), the DCGMA has a long tradition. A forerunner organization was already founded in 1911; the present commission dates back to 1952.
The main tasks of the commission are
The commission uses different media and platforms to disseminate its expertise based on the knowledge of its members:
Carrying out these tasks, the independence of its members is of great importance for the DCGMA. Since 2002 all full and associate members as well as the academic staff of the central office have to declare their potential conflicts of interest to the chairman.
© Arzneimittelkommission der deutschen Ärzteschaft Letzte Änderung: 08.01.2015